Form 4: Denali Therapeutics Director Exercises Options and Sells Shares
SEC Form 4 Filing
Denali Therapeutics director David P. Schenkein exercised stock options and sold shares on November 11, 2024, according to a recent SEC filing.
Summary
- David P. Schenkein, a director at Denali Therapeutics, exercised stock options to acquire 47,165 shares of common stock at a price of $18 per share on November 11, 2024.
- On the same day, Mr. Schenkein sold 27,129 shares at a weighted average price of $32.09 per share and 32,312 shares at a weighted average price of $32.87 per share.
- These sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 12, 2024.
- Following these transactions, Mr. Schenkein directly owns 9,220 shares and indirectly owns 26,232 shares through the David P. Schenkein 2004 Revocable Trust and 31,232 shares through the Amy P. Schenkein 2004 Revocable Trust.
Sentiment
Score: 5
Explanation: The document reflects routine insider trading activity, which is neither particularly positive nor negative. The transactions are part of a pre-arranged plan, suggesting no significant change in the director's outlook on the company.
Industry Context
This is a routine filing related to insider transactions and is common for publicly traded companies. It provides transparency into the trading activities of company directors.
Comparison to Industry Standards
- The use of a Rule 10b5-1 trading plan is a common practice among corporate insiders to avoid accusations of trading on non-public information.
- The reported transactions are typical for directors who receive stock options as part of their compensation.
- The sale prices are within the range of the current market price for Denali Therapeutics stock.
Stakeholder Impact
- The transactions may have a minor impact on the stock price due to the volume of shares sold, but this is likely to be minimal given the pre-planned nature of the sales.
Key Dates
| Date | Description |
|---|---|
| 12/07/2018 | 25% of the shares subject to the option shall vest on this date and an additional 1/48 of the shares vest monthly thereafter. |
| 08/12/2024 | Date the Rule 10b5-1 trading plan was adopted. |
| 11/11/2024 | Date of the stock option exercise and share sales. |
| 11/13/2024 | Date of the SEC filing. |
| 12/06/2027 | Expiration date of the stock options. |
Keywords
Denali Therapeutics, DNLI, insider trading, stock options, share sales, Form 4, David P. Schenkein, Rule 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.